Physician profile
Rajan Narula
NPI 1104021039
$8,056.86
in general payments reported to CMS, 2019-2025
35 companies · $2,153 in 2025
The $2,153 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.05 · 2020: $207 · 2021: $266 · 2022: $664 · 2023: $2,004 · 2024: $2,726 · 2025: $2,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,883.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,133.32 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $783.34 | 2020-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $665.24 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $552.16 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Pfizer INC. | $452.98 | 2023-2025 | |
| Celgene Corporation | $353.97 | 2022-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $325.75 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $278.50 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $244.61 | 2023-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $233.12 | 2023-2025 | Voquezna |
| Mallinckrodt Hospital Products INC. | $212.00 | 2024-2025 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $206.45 | 2022-2025 | Dupixent |
| Redhill Biopharma INC. | $163.99 | 2021-2025 | Talicia, Aemcolo |
| Genzyme Corporation | $153.20 | 2022-2025 | |
| Medtronic, INC. | $139.19 | 2024 | Endoflip |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $138.35 | 2023-2025 | Hadlima, Renflexis |
| Nestle Healthcare Nutrition INC. | $134.87 | 2022-2023 | |
| Intuitive Surgical, INC. | $126.92 | 2025 | |
| Gilead Sciences, INC. | $91.13 | 2020-2024 | |
| Fresenius Kabi USA, LLC | $90.73 | 2023-2024 | Idacio |
| Madrigal Pharmaceuticals | $89.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $79.62 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $63.21 | 2022-2025 | Suflave, Sutab |
| Sandoz INC. | $55.60 | 2024 | Hyrimoz |
| Evoke Pharma, INC. | $53.50 | 2020-2025 | |
| Lucid Diagnostics INC. | $40.74 | 2023 | |
| Ipsen Biopharmaceuticals, INC | $38.40 | 2025 | Iqirvo |
| Teleflex LLC | $26.68 | 2024 | Solesta |
| Lilly USA, LLC | $25.79 | 2025 | Omvoh |
| Amgen INC. | $19.81 | 2023 | Avsola, Amjevita |
| Axonics, INC. | $18.48 | 2024 | Axonics |
| Intercept Pharmaceuticals, INC. | $18.35 | 2022 | |
| Capsovision, INC. | $17.07 | 2024 | Capsocam Plus |
| Echosens North America, INC. | $15.89 | 2022 | |
| Boston Scientific Corporation | $13.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajan Narula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.